Australia TGA ARTG recordSevere acute respiratory syndrome-associated coronavirus IVDs
Australia TGA ARTG Registered Device · Nationwide Asset Management Consolidated Pty Ltd · Hangzhou Testsea Biotechnology Co Ltd · Class IIb · Started November 18, 2022
Good Name: Nationwide Asset Management Consolidated Pty Ltd- Severe acute respiratory syndrome-associated coronavirus IVDs
- Risk Class
- Class IIb
- Product Type
- IVD
- ARTG Category
- IVD
- Start Date
- November 18, 2022
- Effective Date
- November 18, 2022
- Country
- China
- Address
- 3rd Floor Building 6 North No 8-2 Keji Avenue Yuhang District, Hangzhou, Zhejiang Province, 311121
Intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 from symptomatic individuals for self-testing by lay persons (nasal swab).
Access comprehensive regulatory information for Severe acute respiratory syndrome-associated coronavirus IVDs in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIb is sponsored by Nationwide Asset Management Consolidated Pty Ltd, manufactured by Hangzhou Testsea Biotechnology Co Ltd in China. The device registration started on November 18, 2022.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.